Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acerus Pharmaceuticals Corporation (T:ASP)

Business Focus: Pharmaceuticals

Nov 06, 2019 07:30 am ET
Acerus to Report Third Quarter 2019 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB :ASPCF) will announce its third quarter 2019 financial and operating results on Thursday, November 14, 2019 before the market opens. The company will also host a conference call on Thursday, November 14, 2019 at 8:30 a.m. Eastern Time.
Nov 01, 2019 08:30 am ET
Acerus Provides Update on Temporary Unavailability of NATESTO® in Canada and South Korea
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO® in Canada and South Korea, following the previous announcement of the voluntary replacement of certain NATESTO® lots released on the Canadian and South Korean markets.
Oct 23, 2019 07:00 am ET
Acerus Pharma Hosting Key Opinion Leader Meeting on Unique Clinical Evidence of NATESTO® for Treatment of Hypogonadism
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the expanded use of NATESTO® for the treatment of hypogonadism on Wednesday, October 30th in New York City.
Oct 17, 2019 08:30 am ET
New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months
TORONTO, Oct. 17, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO® Spermatogenesis Study as part of the "Late Breaking" Abstract Session at the 75th Annual American Society for Reproductive Medicine (ASRM) Scientific Conference in Philadelphia, PA. Yesterday's presentation was one of only six abstracts accepted as part of this session....
Oct 17, 2019 08:30 am ET
New Data Demonstrates That NATESTO® Increases Serum Testosterone and Improves Symptoms While Maintaining Normal Semen Parameters in Men With Low Testosterone Through Six Months
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO® Spermatogenesis Study as part of the “Late Breaking” Abstract Session at the 75th Annual American Society for Reproductive Medicine (ASRM) Scientific Conference in Philadelphia, PA. Yesterday’s presentation was one of only six abstracts accepted as part of this session.
Sep 30, 2019 05:00 pm ET
Acerus Announces Amendment to Credit Agreement and Waiver of Certain Q3 Financial Covenants
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter from SWK related to certain financial covenants for Q3 2019.
Aug 07, 2019 07:00 am ET
Acerus Reports Second Quarter and Year to Date Fiscal 2019 Financial Results
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”).
Aug 02, 2019 05:00 pm ET
Acerus Announces Temporary Unavailability of NATESTO® in Canada and South Korea
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will voluntarily replace certain NATESTO® lots released in the Canadian and South Korean markets, which is expected to cause temporary shortages in those markets.
Aug 01, 2019 08:05 am ET
NATESTO® Spermatogenesis Study Final Results Accepted for Presentation at the American Society for Reproductive Medicine 75th Annual Scientific Conference
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the NATESTO® Spermatogenesis Study results have been accepted for presentation as a “Late-Breaking Abstract” by the American Society for Reproductive Medicine (ASRM). The study results will be presented at the 75th ASRM Scientific Congress & Expo in Philadelphia, PA October 12-16, 2019.
Jul 30, 2019 07:00 am ET
Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States
TORONTO, July 30, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc. (NASDAQ: AYTU), which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men's Health experience to capture a significant share of the U.S. market for NATESTO®....
Jul 30, 2019 07:00 am ET
Acerus and Aytu Bioscience to Co-promote Natesto® in the United States
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc. (NASDAQ: AYTU), which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men’s Health experience to capture a significant share of the U.S. market for NATESTO®.
Jul 29, 2019 07:00 am ET
Acerus to Report Second Quarter 2019 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the market opens. The company will also host a conference call on Wednesday, August 7, 2019 at 8:30 a.m. Eastern Time.
Jul 24, 2019 05:00 pm ET
Acerus Congratulates US Partner Aytu Bioscience on Listing of NATESTO® on National Pharmacy Benefit Manager’s Formulary
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced today that NATESTO® (testosterone nasal gel) is now on formulary and covered nationwide by a leading national pharmacy benefit manager (PBM) in the United States. This PBM contract provides for unrestricted patient access to NATESTO® across the PBM’s national open formularies and plans that service government clients. Over six million U.S. lives are covered by these prescription plans.
Jul 19, 2019 07:00 am ET
Acerus Announces Closing of US$5 Million Secured Term Loan
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated secured term loan facility (“the Loan”) with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus.(1)
Jul 10, 2019 07:00 am ET
Acerus Provides Business Update on NATESTO®
Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today an update relative to the Company’s NATESTO® business. The Company announced that Hyundai Pharm Co., Ltd. (“Hyundai”) has officially launched the commercialization of NATESTO® in South Korea.
Jul 08, 2019 07:00 am ET
Acerus Announces Publication of Study Results Demonstrating Effectiveness of NATESTO® Regardless of Baseline Symptom Severity
Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today the acceptance of a new manuscript to the Journal of the Endocrine Society, describing how NATESTO® achieves similar symptom improvement, regardless of the degree of a patient’s baseline testosterone deficiency.
Jun 28, 2019 06:57 pm ET
Acerus Announces Amendment to Term Loan Credit Facility
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”).
Jun 27, 2019 05:38 pm ET
Acerus Announces Voting Results for the 2019 Annual Meeting
TORONTO, June 27, 2019 /CNW/ - Acerus Pharmaceuticals Corporation ("Acerus") (TSX:ASP) today announced the voting results from its annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario. The total number of shares represented in person or by proxy at the meeting was 118,253,703, representing 45.27% of the total issued and outstanding Acerus shares.
Jun 27, 2019 07:00 am ET
Acerus Provides Update On Avanafil Health Canada Submission
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening process for the previously announced New Drug Submission (“NDS”) for avanafil. The dossier is now in active review by Health Canada and Acerus expects review completion and, if approved, Notice of Compliance issuance to be in early Q2 of 2020.
Jun 06, 2019 07:00 am ET
Acerus Reaches Mutual Agreement with Innovus Pharma to Terminate Distribution and License Agreement for UriVarx® in Canada
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it has reached a mutual agreement with Innovus Pharmaceuticals, Inc. (OTCQB: INNV) (“Innovus Pharma”), a California-based specialty pharmaceutical company, to terminate the exclusive distributor and license agreement granting Acerus the rights to commercialize UriVarx® in Canada.
May 30, 2019 07:00 am ET
Acerus Signs License Agreement to Nasal Technology with University of Texas at Austin
Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today that it has signed a patent license agreement (the “PLA”) with the University of Texas at Austin for technology related to the nasal administration of testosterone. The newly patented, aqueous-based, nasal delivery technology was developed by Robert Josephs, a UT Austin Professor of Clinical and Social Psychology, and Craig Herman, a Doctor of Pharmacy at MedCara Pharmaceuticals in Conrad, Iowa. Under the PLA, Acerus has licensed worldwid
May 13, 2019 07:00 am ET
Acerus Reports First Quarter 2019 Financial Results
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three-month period ended March 31, 2019 (“Q1-2019). Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”).
May 08, 2019 07:00 am ET
Acerus Approved to Trade on the OTCQB Venture Market under the Symbol ASPCF
Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today its shares have been approved to be quoted on the OTCQB Venture Market and will trade under the symbol “ASPCF” effective immediately. Real-time information, quotes and the trading statistics can be found at www.otcmarkets.com.
May 06, 2019 07:00 am ET
Acerus to Report First Quarter 2019 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its first quarter 2019 financial and operating results on Monday May 13, 2019 before the market opens. The company will host a conference call on Monday, May 13, 2019 at 8:30 a.m. Eastern Time.
Apr 29, 2019 07:00 am ET
Acerus Engages Paradigm Capital to Pursue Cannabinoid Opportunities
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has engaged Paradigm Capital Inc. (“Paradigm”) as its financial advisor to leverage its proprietary nasal delivery technology in cannabinoid applications through licensing, partnership agreements or other transactions with interested parties.
Apr 24, 2019 07:00 am ET
Acerus to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Edward Gudaitis, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference. Mr. Gudaitis’ address will take place at the Metro Toronto Convention Centre, 255 Front Street W, Toronto, Ontario on May 1, 2019 at 10:00 a.m. Eastern Time.
Mar 29, 2019 07:00 am ET
Acerus Pharmaceuticals Corporation Announces Closing of Private Placement
Acerus Pharmaceuticals Corporation (the “Company”) (TSX:ASP) is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”) of 23,230,772 common shares of the Company (the “Common Shares”) to directors and management of the Company at a price of $0.195 per Common Share for aggregate proceeds of approximately $4.53 million.
Mar 05, 2019 07:00 am ET
Acerus Reports Fourth Quarter and Full Year 2018 Financial Results
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP) today reported its financial results for the three and twelve-month period ended December 31, 2018. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”).
Mar 04, 2019 07:00 am ET
Acerus Files a New Drug Submission for Avanafil in Canada
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has filed a New Drug Submission (“NDS”) for Avanafil with Health Canada. Avanafil, a treatment for erectile dysfunction (“ED”), is a new, second generation PDE5 inhibitor, which has increased receptor specificity for fast onset of action and lower off-target side effects.
Feb 27, 2019 07:00 am ET
Acerus Provides Business Update on NATESTO®
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) announced today two updates relative to the Company’s NATESTO® business. First, the Company announced making the first shipment of NATESTO® to South Korea. Second, the Company announced 2 new, peer-reviewed publications describing results from the NATESTO® My-T study.
Feb 26, 2019 07:00 am ET
Acerus to Report 2018 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP) will announce financial results for the three and twelve month periods ending December 31, 2018 on Tuesday, March 05, 2019 before market opens. The company will host a conference call on Tuesday, March 05, 2019 at 8:30 a.m. Eastern Time.
Jan 25, 2019 07:00 am ET
Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor™ Application
Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has received a Notice of Deficiency-Withdrawal Letter (“Notice”) for its GynoflorTM New Drug Submission. The Company has 30 days to decide if it wishes to file a Letter of Intent to file a Request for Reconsideration of the Notice.
Jan 11, 2019 06:00 pm ET
Acerus Announces Reporting of Anticipated Shortage of ESTRACE®
Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has reported an anticipated shortage of certain doses of ESTRACE® on the Drug Shortages Canada website in relation to supply issues arising from the Company’s contract manufacturer.
Dec 11, 2018 07:00 am ET
Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today providing results of a Phase 1 clinical trial (the “trial”) testing a proprietary intranasal formulation of a tetrahydrocannabinol (“THC”)-rich cannabis oil in healthy volunteers.
Nov 26, 2018 07:00 am ET
Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO®
Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today providing an update on a number of significant operational and research achievements related to NATESTO®, one of the Company’s core strategic assets.
Nov 06, 2018 07:00 am ET
Acerus Reports Third Quarter 2018 Financial Results
Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) today reported its financial results for the three and nine months ended September 30, 2018. Unless otherwise noted, all amounts are in U.S. dollars.
Oct 31, 2018 07:00 am ET
Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe
Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) today announced the signing of an amendment to its existing licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate mbH (“medac”), expanding the German pharmaceutical company’s exclusive right to market NATESTO® in the totality of the 28 current EU member countries (including the United Kingdom) as well as Norway, Liechtenstein, Iceland, Turkey (including Turkish Cyprus), Australia, New Zealand, Israel and South Africa. In addition,
Oct 30, 2018 05:00 pm ET
Acerus to Report Third Quarter 2018 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its third quarter 2018 financial and operating results on Tuesday November 6, 2018 before market opens. The company will host a conference call on Tuesday, November 6, 2018 at 8:30 a.m. Eastern Time.
Oct 30, 2018 08:00 am ET
Acerus Announces Executive Leadership Changes in Corporate Finance
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced that Robert M. Motz will join the Company as Chief Financial Officer, effective today, and will become a member of Acerus’ Senior Leadership Team. The Company also announced that Ken Yoon, the Company’s current Chief Financial Officer, has decided to leave Acerus at the end of October to pursue other opportunities.
Oct 24, 2018 05:00 pm ET
Acerus Announces Initiation of a Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced first dosing of subjects in a Phase 1 clinical trial testing a proprietary intranasal formulation of a tetrahydrocannabinol (“THC”)-rich cannabis oil in healthy volunteers. This is a preliminary step in a broader strategy focused on identifying additional applications for Acerus’ proprietary nasal delivery technology, including for prescription medical marijuana.
Oct 12, 2018 09:00 am ET
Acerus Announces Closing of US$11 Million Term Loan Credit Facility
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced that it has entered into a senior secured term loan credit facility with SWK Funding LLC (“SWK”) for up to US$11 million (the “New Facility”). An initial tranche of US$9 million of the New Facility was available at closing, with the remaining US$2 million of the New Facility becoming available upon satisfaction of certain future conditions. The New Facility replaces the CDN$5 million senior secured credit facility with Quantius In
Sep 17, 2018 07:00 am ET
Acerus Announces Publication of Manuscript Reporting Early Data from Partner-Sponsored Natesto® Spermatogenesis Study
Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) today announced the publication of a clinical trial update in the journal European Urology Focus on the effects of Natesto® on reproductive hormones and semen parameters. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology, is the study's principal investigator. The Company’s partner, Aytu BioScience Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focus
Aug 13, 2018 07:00 am ET
Acerus Reports Second Quarter 2018 Financial Results
Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) today reported its financial results for the three months and six months ended June 30, 2018. Unless otherwise noted, all amounts are in U.S. dollars.
Aug 03, 2018 07:00 am ET
Acerus to Report Second Quarter 2018 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its second quarter 2018 financial and operating results on Monday August 13, 2018 before market opens. The company will host a conference call on Monday, August 13 2018 at 8:30 a.m. Eastern Time.
Jun 28, 2018 04:51 pm ET
Acerus Announces Voting Results for the 2018 Annual and Special Meeting
Acerus Pharmaceuticals Corporation (“Acerus”) (TSX:ASP) today announced the voting results from its annual and special meeting of shareholders held on June 28, 2018 in Toronto, Ontario. The total number of shares represented in person or by proxy...
Jun 28, 2018 09:42 am ET
Acerus Pharmaceuticals Corporation Announces Closing of $6.61 Million Bought Deal Financing and Exercising of the Over-Allotment
Acerus Pharmaceuticals Corporation (the “Company”) (TSX:ASP) is pleased to announce that it has closed the previously announced issue and sale of 22,041,705 units (“Units”) of the Company at a price of $0.30 per Unit, which includes 2,875,005 Units...
Jun 14, 2018 07:00 am ET
Acerus Announces Approval of NATESTO® in South Korea
Acerus Pharmaceuticals Corporation (TSX:ASP) (Acerus or the Company”) announced today that Hyundai Pharm Co., Ltd. (Hyundai), Acerus’ licensee, reported that South Korea’s Ministry of Food and Drug Safety (MFDS) has approved NATESTO® for the treatment of hypogonadism.
Jun 07, 2018 10:53 am ET
Acerus Pharmaceuticals Announces Upsize of its Previously Announced Bought Deal Financing to $5.75 Million
Acerus Pharmaceuticals Corporation (the “Company”) (TSX:ASP) is pleased to announce that it has entered into a revised agreement with Mackie Research Capital Corporation (the “Underwriter”), to increase the size of the previously announced bought...
Jun 06, 2018 04:06 pm ET
Acerus Pharmaceuticals Corporation Announces $5 Million Bought Deal Financing
Acerus Pharmaceuticals Corporation (the “Company”) (TSX:ASP) is pleased to announce that it has entered into an agreement with Mackie Research Capital Corporation (the “Underwriter”), whereby the Underwriter has agreed to purchase, on a bought-deal...
Jun 05, 2018 09:30 pm ET
Acerus Announces Resignation of Director
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that Mr. Luc Mainville has stepped down as a director of the company.
May 29, 2018 07:00 am ET
Acerus Acquires Canadian Rights to Novel Pain Relief Product for Gynecological Procedures from Pharmanest
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has entered into an exclusive agreement to commercialize Pharmanest AB (“Pharmanest”) Short Acting Lidocaine product (“SHACT”), a novel pain relief drug device combination in Canada.
May 17, 2018 07:00 am ET
Acerus Announces Buyout of All Obligations under the Mattern License Agreement
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today reported that it has entered into an agreement with Mattern Pharma AG (“Mattern”) to buy out all of its obligations (the “Buyout”) under the Amended and Restated Intellectual Property Rights and Product Development Agreement, dated December 21, 2013 (as amended) (“License Agreement”), including all of its future royalty payment obligations.
May 15, 2018 07:00 am ET
Acerus Reports First Quarter 2018 Financial Results
Acerus Pharmaceuticals Corporation :
May 08, 2018 04:30 pm ET
Acerus to Report First Quarter 2018 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its first quarter 2018 financial and operating results on Tuesday May 15, 2018 before market opens. The company will host a conference call on Tuesday, May 15, 2018 at 8:30 a.m. Eastern Time.
Apr 23, 2018 07:00 am ET
Acerus Secures Additional CDN $2M under the Quantius Loan Facility
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) announced today that it has received an additional $2 million under its secured term credit facility with Quantius Inc. (the “Quantius Facility”). This additional $2 million represented the second tranche of the $5 million Quantius Facility entered into late in 2017 and was conditional on Acerus achieving certain commercial milestones. These conditions included our U.S. Partner for NATESTO® reaching a set number of total prescriptions per month as well as Acerus,
Apr 18, 2018 07:00 am ET
Acerus to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Edward Gudaitis, the incoming President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the seventh annual Bloom Burton & Co. Healthcare Investor Conference. Mr. Gudaitis’ address will take place at the Sheraton Centre Toronto Hotel on May 3, 2018 at 3:30 p.m. Eastern Time. The Acerus team will also be participating in one-to-one meetings with industry stakeholders during the conference.
Apr 13, 2018 07:00 am ET
Acerus Announces Licensing of NATESTO® in 19 Central and Latin American Countries
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced the signing of an agreement granting Producto Científicos, S.A. de C.V (“Carnot Laboratorios”) the exclusive right to market NATESTO® in 19 Central and Latin American countries (Mexico, Argentina, Columbia, Peru, Chile, Ecuador, Guatemala, El Salvador, Nicaragua, Honduras, Panama, Costa Rica, Cuba, Dominican Republic, Venezuela, Bolivia, Uruguay, Paraguay and Haiti). Carnot Laboratorios is a Latin American pharmaceutical company founded in 1941,
Apr 10, 2018 07:00 am ET
Acerus Announces Settlement of Melnyk Litigation
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that the Company and certain of its present and former directors and officers have reached a settlement with Eugene Melnyk pursuant to which Mr. Melnyk has agreed to a dismissal of the two actions that he commenced against the Company and certain of its directors and officers in the Ontario Superior Court of Justice in 2016. Mr. Melnyk will also withdraw his notice of motion for leave to appeal the decision of the Divisional Court dismissing his appeal of th
Apr 09, 2018 07:00 am ET
Acerus Announces Launch of URIVARX® in Canada
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced the launch of URIVARX® in Canada less than 3 months after securing the exclusive Canadian rights to the product from Innovus Pharmaceuticals, Inc. (OTCQB: INNV) (“Innovus”) earlier in the year.
Apr 05, 2018 04:30 pm ET
Acerus to Present at the Next CHINABIO® Partnering Forum
Acerus Pharmaceuticals Corporation (TSX:ASP) today announced that is has been selected to present at the annual CHINABIO® Partnering Forum 2018 to be held in Suzhou, China, on April 25 and 26, 2018.
Mar 29, 2018 08:30 am ET
Acerus Announces Executive Leadership Change
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has appointed Mr. Edward Gudaitis as President and Chief Executive Officer. Mr. Luc Mainville will continue to act as Interim CEO and will work with Mr. Gudaitis to ensure a smooth transition. Thereafter, Mr. Mainville will resume his post on the Board of Directors of Acerus. Both changes are effective May 1, 2018.
Mar 28, 2018 07:00 am ET
Acerus Expands its Urology Franchise by Acquiring Canadian Rights to Stendra® from Metuchen Pharmaceuticals
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has entered into an exclusive distributor and license agreement with Metuchen Pharmaceuticals LLC (“Metuchen”), a privately-held specialty pharmaceutical company dedicated to improving men’s health, granting Acerus the exclusive rights to commercialize STENDRA® in Canada.
Mar 21, 2018 06:00 am ET
Acerus Reports Fourth Quarter and Full Year 2017 Financial Results
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP) today reported its financial results for the three and twelve-month period ended December 31, 2017. Unless otherwise noted, all amounts are in U.S. dollars.
Mar 14, 2018 05:30 pm ET
Acerus to Report 2017 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP) will announce financial results for the three and twelve month periods ending December 31, 2017 on Wednesday, March 21, 2018 before market opens. The company will host a conference call on Wednesday, March 21, 2018 at 8:30 a.m. Eastern Time.
Mar 02, 2018 07:00 am ET
Acerus Comments on Decision Regarding Litigation
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that the Divisional Court of the Ontario Superior Court of Justice has dismissed the appeal brought by Mr. Eugene Melnyk of the Order of the Honourable Justice Wilton-Siegel dismissing Mr. Melnyk’s motion for leave to commence a derivative action in the name of the Company against certain of the Company’s directors and officers. “We vigorously defended against this appeal brought by Mr. Melnyk and are very happy with this decision,” said Luc Mainville, Inter
Feb 01, 2018 09:00 pm ET
Acerus Pharma’s NATESTO® to Be Listed for Public Reimbursement in Quebec, Building on Strong 28% Increase in Natesto’s Canadian Prescriptions in Q4 2017
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has received notice from Quebec’s National Institute for Excellence in Health and Social Services (INESSS) of a positive recommendation to the Health Minister for the inclusion of NATESTO® on the list of medications of the Régie de l’assurance maladie du Québec. This recommendation takes effect on February 1st, 2018.
Jan 08, 2018 06:00 am ET
Acerus Enters into a Licensing Agreement with Innovus to Commercialize UriVarx® in Canada
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has entered into an exclusive distributor and license agreement with Innovus Pharmaceuticals, Inc. (OTCQB: INNV) (“Innovus”), a California-based specialty pharmaceutical company developing safe and effective over-the-counter medicines, granting Acerus the exclusive rights to commercialize UriVarx® in Canada.
Dec 24, 2017 09:00 am ET
Acerus Receives Notice of Deficiency from Health Canada for Gynoflor™
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has received a Notice of Deficiency (“NOD”) for its GynoflorTM New Drug Submission.
Dec 20, 2017 07:00 am ET
Acerus Enters into a Licensing Agreement with Viramal to Commercialize the Elegant™ Franchise in Canada
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has entered into a license, development and supply agreement with Viramal Limited (“Viramal”), a London-based specialty pharmaceutical company developing therapeutics that improve the quality of women’s health, granting Acerus the exclusive rights to commercialize the Elegant™ franchise in Canada.
Dec 07, 2017 07:30 am ET
Acerus Appoints Mr. Mark Lievonen to its Board of Directors
Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the appointment of Mr. Mark Lievonen to its Board of Directors. The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors. Mr. Lievonen has also been appointed to the Audit Committee and will serve as its Chair.
Dec 06, 2017 07:30 am ET
Acerus Enters into Loan Facility to Support Anticipated Product Launch and Sales and Marketing Initiatives
Acerus Pharmaceuticals Corporation (TSX:ASP) today reported that it has entered into a senior secured term credit facility with Quantius Inc. for up to Cdn. $5 million. $3 million was available at closing, with the remaining $2 million becoming available upon satisfaction of certain future conditions, including 1) our U.S. Partner for NATESTO® achieving a set number of prescriptions per month, and 2) maintaining ESTRACE® sales at a set minimum level.
Nov 30, 2017 07:00 am ET
Acerus Secures CDN$1.6 Million of New NATESTO® Orders from Its U.S. Licensee Aytu Bioscience
Acerus Pharmaceuticals Corporation (TSX:ASP) today announced CDN $1.6 million worth of NATESTO® purchase orders from its U.S. licensee Aytu BioScience (NASDAQ: AYTU). The current orders have been placed as a result of the acceleration of NATESTO® product sales in the United States and will support Aytu’s expected inventory requirements for the first part of 2018. These purchase orders include the delivery of an initial product shipment by Acerus to Aytu in November. As per the terms of the License and Supply Agreement with Aytu, revenues associa
Nov 23, 2017 07:00 am ET
Acerus Announces Licensing Of NATESTO® In Brazil
Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement granting Apsen Farmacêutica (Apsen) the exclusive right to market NATESTO® in Brazil. Apsen is a leading Brazilian based pharmaceutical company with over 40 products and 1,100 employees in that country.
Nov 07, 2017 07:00 am ET
Acerus Reports Third Quarter 2017 Financial Results
Acerus Pharmaceuticals Corporation (TSX: ASP) today reported its financial results for the three and nine-month period ended September 30, 2017. Unless otherwise noted, all amounts are in U.S. dollars.
Oct 31, 2017 07:00 am ET
Acerus to Report Third Quarter 2017 Financial Results and Host Investor Call
Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its third quarter 2017 financial and operating results on Tuesday, November 7, 2017 before market opens. The company will host a conference call on Tuesday, November 7, 2017 at 8:30 a.m. Eastern Time.
Oct 17, 2017 07:00 am ET
Acerus Announces Licensing of NATESTO® in South East Asian Countries
Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement granting Eu Hwa Pte LTD. (“EU”) the exclusive right to market NATESTO® in Thailand, Malaysia/Brunei, Singapore, Vietnam, Philippines, Hong Kong/Macau and one other small South East Asian country. EU is a subsidiary of one of Taiwan’s largest pharmaceutical companies, which has more than 800 employees worldwide as well as more than 300 dedicated pharmaceutical commercial employees with expertise across multiple therapeutic areas in South East Asia,
Oct 02, 2017 10:14 am ET
Acerus announces executive leadership change
TORONTO, Oct. 2, 2017 /CNW/ - Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Mr. Tom Rossi, President and Chief Executive Officer, will depart from the Company on October 2, 2017 to pursue other opportunities.
Apr 25, 2016 08:45 am ET
Aytu BioScience Enters $2 Billion Testosterone Replacement Market with Acquisition of U.S. Commercial Rights to Natesto®
ENGLEWOOD, Colo., April 25, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology today announced the exclusive licensing of its third commercial-stage urology product in just 11 months, with the execution of a long-term, exclusive license agreement with an affiliate of Acerus Pharmaceuticals Corporation (TSX: ASP) for the U.S. commercial rights to Natesto® (testosterone) Nasal Gel.  Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Adminis...